ADC Therapeutics SA (ADCT)
Automate Your Wheel Strategy on ADCT
With Tiblio's Option Bot, you can configure your own wheel strategy including ADCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADCT
- Rev/Share 0.6547
- Book/Share -2.2222
- PB -1.5795
- Debt/Equity -1.405
- CurrentRatio 4.4639
- ROIC -0.5825
- MktCap 348115833.0
- FreeCF/Share -1.2631
- PFCF -2.571
- PE -2.5112
- Debt/Assets 1.2281
- DivYield 0
- ROE 0.8051
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
ADC Therapeutics SA (NYSE:ADCT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and welcome to ADC Therapeutics' First Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference call over to Marcy Graham, Investor Relations and Corporate Affairs Officer.
Read More
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.56 per share a year ago.
Read More
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
LAUSANNE, Switzerland , May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates.
Read More
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs LAUSANNE, Switzerland , April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based antibody drug conjugates (ADCs) targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ACST2) as presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. "We …
Read More
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral
ADC Therapeutics SA (NYSE:ADCT ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Kelly Shi - Jefferies Michael Schmidt - Guggenheim Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all lines are in listen-only mode.
Read More
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Published: March 24, 2025 by: Seeking Alpha
Sentiment: Positive
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion.
Read More
About ADC Therapeutics SA (ADCT)
- IPO Date 2020-05-18
- Website https://www.adctherapeutics.com
- Industry Biotechnology
- CEO Dr. Ameet Mallik M.B.A., M.S.
- Employees 263